Posted on December 1, 2022
There are times in the life of a stock when it pays to take out insurance.
And in the investment world that means buying PUTs.
Here at A Jew and His Money, we’re big believers in the life cycle of securities, and taking proper care of them from birth through old age. But it’s a rare day when we just suggest a straight PUT purchase on a stock.
And today is no exception.
What we’ve found, instead, is a goldmine opportunity to profit from Merck’s (NYSE:MRK) current amble outside the 83rd floor window of the Chrysler Building.
MRK has set seven new all-time highs over the last eight trading sessions, and the drug-pusher’s bulls are certain the run will never end.
But we beg to disagree.
We’ve seen the numbers and the news, and despite the fact that the vaxx fanatics who run the company just took over Imago Biosciences, our considered response is … MEH.
It’s our view that Merck is about to take it on the chin—and we’re not alone.
Some very well-positioned individuals also agree with us.
But more on that in a moment.
First, let’s take a mosey through the fundamentals. Before we offer you the whopper.
Anyway, the numbers are like this—
Many happy returns!